Vitamin B12 benefits — what deficiency correction delivers, and what it does not

The benefits of vitamin B12 are unusually clear-cut, on one condition: they apply to people who do not have enough of it. In deficiency, repletion reverses a specific anaemia and can stop a specific neurological injury from becoming permanent — an outcome few interventions in this catalogue can claim. In someone whose B12 status is already normal, the marketed benefits of a shot are not supported, because the biochemistry has nothing left to correct.

Every honest B12 question therefore reduces to a diagnostic one: what is this person's actual status? That question is answered with blood tests, not with a symptom checklist.

B12 is a required cofactor for two enzymes — methionine synthase and methylmalonyl-CoA mutase — which places it at the centre of DNA synthesis, myelin maintenance, and red-cell production. It cannot be synthesised by the human body and must come from animal-source foods or supplements. The Recommended Dietary Allowance for adults is 2.4 mcg per day (NIH Office of Dietary Supplements).

Absorption is where B12 becomes interesting. Dietary B12 must be released from food protein by stomach acid, then bound to intrinsic factor produced by gastric parietal cells, then absorbed in the terminal ileum. That multi-step pathway has several failure points, and it saturates: intrinsic factor capacity is exceeded at roughly 1–2 mcg per dose, which is why absorption of a large oral dose falls to about 2% at 500 mcg and 1.3% at 1,000 mcg.

Deficiency produces two recognised clinical syndromes. The haematologic one is megaloblastic anaemia, with large, immature red cells and the fatigue and breathlessness that follow. The neurological one includes peripheral neuropathy and subacute combined degeneration of the spinal cord — and it can become irreversible if the deficiency persists long enough. Sally Stabler's clinical-practice review in the New England Journal of Medicine is the standard reference for how deficiency is diagnosed and managed (N Engl J Med 2013;368:149-60).

Repletion corrects the haematologic abnormalities reliably. Neurological recovery depends on how long the deficiency ran before it was found, which is the practical reason identification matters more than supplementation. This is also why injectable cyanocobalamin exists as a labelled prescription treatment rather than a wellness product: its indication is B12 deficiency from malabsorption, in conditions including pernicious anaemia, gastrointestinal pathology or surgery, and bowel or pancreatic malignancy (cyanocobalamin injection label, DailyMed).

O'Leary and Samman's review in Nutrients separates the two mechanisms: deficiency is usually caused by malabsorption, though dietary inadequacy is common in older adults, vegans, and vegetarians with poor diets. In older people the dominant mechanism is protein-bound malabsorption associated with atrophic gastritis — the stomach no longer produces enough acid to free B12 from food protein, so intake can look adequate while status is not (O'Leary and Samman, Nutrients 2010).

The recognised risk groups are therefore specific rather than general:

• Older adults, where reported prevalence ranges from about 3% to 43% depending on the definition used.
• People with pernicious anaemia — autoimmune loss of intrinsic factor.
• People with coeliac disease, Crohn's disease, or prior gastrointestinal surgery including bariatric procedures.
• Vegans and strict vegetarians, and infants of vegan mothers.
• People on long-term metformin or acid-suppressing medication.

The same review notes that subclinical deficiency is subtle and often unrecognised, with possible long-term consequences for pregnancy outcomes and vascular, cognitive, bone and eye health — framed there as areas of concern rather than established causal effects.

B12 shots are sold for energy, mood, metabolism, and weight loss. The claim has a plausible-sounding origin, because a genuinely deficient person treated with B12 often does feel dramatically better — the anaemia resolves. Generalising that experience to people with normal B12 status is where the reasoning fails: there is no trial evidence that supplemental B12 increases energy or reduces fatigue in someone who is replete, and the excess is largely excreted.

Two adjacent claims deserve the same scrutiny. B12 with folate reliably lowers homocysteine, yet the O'Leary and Samman review notes that B-vitamin supplementation trials "did not show the expected reductions in risk of cardiovascular disease" — a textbook case of a biomarker moving without the outcome following. And supplementation has not been shown to prevent cognitive decline in people without deficiency.

The useful reframing is that B12 is not a stimulant with a dose-response curve; it is a cofactor with a threshold. Above the threshold, more does not do more. See B12 dosing for how repletion regimens are actually structured.